Catching cancer by the tail: New perspectives on the use of kinase inhibitors

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3645-3647

  Khanna, Chand ^a   Gordon, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AB 1010; ANTINEOPLASTIC AGENT; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SU 11654; SUNITINIB; TOCERANIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; CUTANEOUS MAST CELL TUMOR; DOG; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SKIN CANCER; TREATMENT RESPONSE;

ANIMALS; DOG DISEASES; DOGS; INDOLES; MAST-CELL SARCOMA; NEOPLASM RECURRENCE, LOCAL; PYRROLES; RANDOM ALLOCATION; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 66649092624     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0132     Document Type: Short Survey

References (11)

1. London C, Malpas PB, Michels GM, et al.Multicenter, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-3865
2. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-111 PubMed doi:10.1593/neo.05622.
3. Downing S, Chien MB, Kass PH, Moore PE, London CA. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:1718-1723 PubMed doi:10.2460/ajvr. 2002.63.1718. (Pubitemid 35469646)
4. London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-97. PubMed doi:10.1016/S0301-472X(98)00075-77 (Pubitemid 29181445)
5. Du CY, Shi YQ, Zhou Y, Fu H, Zhao G. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol 2008;98:175-178 PubMed doi:10.1002/jso.21104.
6. Braconi C, Bracci R, Cellerino R.Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets 2008;8:359-366 PubMed doi:10.2174/156800908785133169.
7. Liao AT, McMahon M, London C. Characterization, expression and function of c-Met in canine spontaneous cancers. Vet Comp Oncol 2005;3:61-72. doi:10.1111/j.1476-5810.2005.00067.x.
8. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003;9:5729-5734 PubMed. (Pubitemid 37499497)
9. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768 PubMed. (Pubitemid 36842122)
10. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93. PubMed doi:10.1182/blood-2004-05-1846. (Pubitemid 40170865)
11. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-1309 PubMed doi:10.1111/j.1939-1676.2008.0190.x.